, the combination
agent aspirin Ã¾ dipyridamole, and dual antiplatelet therapy have all been investigated in this clinical scenario but
the optimal regimen is not clear. In the Clopidogrel vs
Aspirin in Patients at Risk of Ischemic Events (CAPRIE)
trial, there was a small advantage of clopidogrel over
aspirin in reducing overall ischemic events.131 However,
analysis of a subset of patients with a prior